Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Lee Johnson

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Stem Cell Research|December 28, 2020
Generation of an iPSC line (AKOSi004-A) from fibroblasts of a female adult NPC1 patient, carrying the compound heterozygous mutation p.Val1023Serfs*15/p.Gly992Arg and of an iPSC line (AKOSi005-A) from a female adult control individualChristin Völkner, Maik Liedtke, Janine Petters, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2017
Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site InspectionsJanice Kim, Harpreet Singh, Kassa Ayalew, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 19, 2018
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute WorkshopPaul G Kluetz, Bindu Kanapuru, Steven Lemery, et al.
JAMA|February 8, 2018
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO ExtensionMelanie Calvert, Derek Kyte, Rebecca Mercieca-Bebber, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Stem Cell Research|December 28, 2020
Generation of an iPSC line (AKOSi004-A) from fibroblasts of a female adult NPC1 patient, carrying the compound heterozygous mutation p.Val1023Serfs*15/p.Gly992Arg and of an iPSC line (AKOSi005-A) from a female adult control individualChristin Völkner, Maik Liedtke, Janine Petters, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2017
Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site InspectionsJanice Kim, Harpreet Singh, Kassa Ayalew, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 19, 2018
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute WorkshopPaul G Kluetz, Bindu Kanapuru, Steven Lemery, et al.
JAMA|February 8, 2018
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO ExtensionMelanie Calvert, Derek Kyte, Rebecca Mercieca-Bebber, et al.
Pageof 3